Back
Compare AU
Compare VAE vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard FTSE Asia Ex Japan Shares Index ETF (VAE) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VAE | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 586 | 73 |
Median incremental investment | $1,050.00 | $653.58 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,219.36 | $1,339.20 |
Average age group | 26 - 35 | > 35 |
Key Summary
VAE | CURE | |
|---|---|---|
Strategy | Vanguard FTSE Asia ex Japan Shares Index ETF objective is to track the performance of the FTSE Asia Pacific ex Japan, Australia and New Zealand Index (with net dividends reinvested) in Australian dollars before accounting for fees, expenses and tax. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Taiwan Semiconductor Manufacturing Co. Ltd. (6.57 %) Tencent Holdings Ltd. (4.32 %) Samsung Electronics Co. Ltd. (3.96 %) | Exact Sciences Corp (3.23 %) Alnylam Pharmaceuticals Inc (3.16 %) Neurocrine Biosciences Inc (2.89 %) |
Top 3 industries | Information Technology (21.30 %) Other (15.91 %) Financials (15.36 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | China (31.42 %) India (23.33 %) Taiwan (18.76 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.4 % | 0.45 % |
Key Summary
VAE | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | FTSE Asia Pacific ex Japan Australia and New Zealand Net - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.45 % |
Price | $83.91 | $43.20 |
Size | N/A | $30.325 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.09 % | 4.24 % |
Market | ASX | ASX |
First listed date | 11/12/2015 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VAE | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 586 | 73 |
Median incremental investment | $1,050.00 | $653.58 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,219.36 | $1,339.20 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
VAE | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VAE | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |